Dendreon Photos

Morris Plains Campus
Dendreon

+ Add Photo

Dendreon Reviews

2.8
96 Reviews
Rating Trends
Recommend to a friend
Approve of CEO
Dendreon President & CEO John H. Johnson
John H. Johnson
38 Ratings
  • Great place.

    • Comp & Benefits
    • Work/Life Balance
    • Senior Management
    • Culture & Values
    • Career Opportunities
    Former Employee - Manufacturing Associate
    Former Employee - Manufacturing Associate

    I worked at Dendreon

    Pros

    Helping men with prostate cancer. Good pay good benefits. New facility with a ton of great co workers.

    Cons

    The ongoing risk of layoffs was always looming. Unfortunately this caused most of the better employees to look for other work.

    Recommends
    Negative Outlook
    Disapproves of CEO

Dendreon Interviews

Updated Feb 24, 2015
Updated Feb 24, 2015

Interview Experience

Interview Experience

52%
29%
17%

Getting an Interview

Getting an Interview

63%
12%
10%

Interview Difficulty

2.8
Average

Interview Difficulty

Hard

Average

Easy
  1.  

    Supervisor Interview

    Anonymous Interview Candidate
    Anonymous Interview Candidate
    Interview Details

    The hiring process was long and drawn out. Seems they are looking for "yes men/women" as opposed to independent thinkers. They do not seem to really look for qualified candidates during the interview process.

    Accepted Offer

Dendreon Awards & Accolades

Let us know if we're missing any workplace or industry recognition – Add an award

Additional Info

Unlock Profile
Website www.dendreon.com
Headquarters Seattle, WA
Size 500 to 999 Employees
Founded 1992
Type Company - Public (DNDN)
Industry Biotech & Pharmaceuticals
Revenue $100 to $500 million (USD) per year

Dendreon wants to boost your immunity from the start. It is developing therapeutic vaccines that help the body's immune system fight cancer by targeting dendritic cells, which initiate an immune response to disease-causing antigens. Its sole commercial product, Provenge, is a therapeutic vaccine that targets prostate cancer. Provenge gained the status of being the first therapeutic cancer vaccine to receive FDA approval in 2010. Dendreon is also working on a therapeutic vaccine to treat breast, bladder, and ovarian cancers, and it has research programs investigating... More

Work at Dendreon? Share Your Experiences

Dendreon

 
Click to Rate
or